Latest news

Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Debiopharm Strategic Fund announces FDA clearance of Portfolio Company Immunexpress’ first Test

Debiopharm International SA Appeals to the Supreme Court regarding Nippon Kayaku Co., Ltd. case

Appel à projets pour la 2ème édition du Challenge Debiopharm Inartis

GenePOC announces product launch in Europe and Middle East

Debiopharm Investment strengthens its presence in the renewable energy sector

GenePOC to Announce CE Marking of its revogene™ Instrument and its Second Test, CDiff

Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients

Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe